Resistance to targeted therapies: a role for microRNAs?
作者： Cristina Migliore , Silvia Giordano
DOI: 10.1016/J.MOLMED.2013.08.002
关键词: Bioinformatics 、 Biology 、 microRNA 、 Cancer therapy 、 Cancer treatment 、 Oncogene Addiction 、 Therapeutic approach 、 Context (language use) 、 Resistance (ecology) 、 Molecular medicine 、 Molecular biology
摘要: The discovery of oncogene addiction dramatically changed the therapeutic approach for cancer treatment, and many drugs targeting specific molecular alterations are now in clinics. Despite big success these new compounds, main limit to their efficacy is represented by resistance therapy. alteration activity or expression proteins has already been linked onset resistance, but recent evidence indicates a role microRNAs (miRNAs) as well. In this context, idea exploiting miRNAs predictors response therapy represents an intriguing possibility. purpose review address relationship between targeted therapies resistance.
elsevier.com
sci-hub.se 参考文章(83)
Barbara A. Burtness, Ranee Mehra, Roger B. Cohen, The Role of Cetuximab for the Treatment of Squamous Cell Carcinoma of the Head and Neck Clinical advances in hematology & oncology. ,vol. 6, pp. 742- 750 ,(2008)
Eun-Jung Jung, Libero Santarpia, Juyeon Kim, Francisco J. Esteva, Erica Moretti, Aman U. Buzdar, Angelo Di Leo, Xiao-Feng Le, Robert C. Bast, Soon-Tae Park, Lajos Pusztai, George A. Calin, Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients Cancer. ,vol. 118, pp. 2603- 2614 ,(2012) , 10.1002/CNCR.26565
Andreas Gschwind, Oliver M. Fischer, Axel Ullrich, The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer. ,vol. 4, pp. 361- 370 ,(2004) , 10.1038/NRC1360
David J. Tweardy, Jennifer Rubin Grandis, Elevated Levels of Transforming Growth Factor α and Epidermal Growth Factor Receptor Messenger RNA Are Early Markers of Carcinogenesis in Head and Neck Cancer Cancer Research. ,vol. 53, pp. 3579- 3584 ,(1993)
A Bergamaschi, B S Katzenellenbogen, Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance Oncogene. ,vol. 31, pp. 39- 47 ,(2012) , 10.1038/ONC.2011.223
L. Zhang, J. Huang, N. Yang, J. Greshock, M. S. Megraw, A. Giannakakis, S. Liang, T. L. Naylor, A. Barchetti, M. R. Ward, G. Yao, A. Medina, A. O'Brien-Jenkins, D. Katsaros, A. Hatzigeorgiou, P. A. Gimotty, B. L. Weber, G. Coukos, microRNAs exhibit high frequency genomic alterations in human cancer Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 9136- 9141 ,(2006) , 10.1073/PNAS.0508889103
Tong Sun, Ming Yang, Shaoyong Chen, Steven Balk, Mark Pomerantz, Chen-Lin Hsieh, Myles Brown, Gwo-Shu Mary Lee, Philip W. Kantoff, The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. The Prostate. ,vol. 72, pp. 1093- 1103 ,(2012) , 10.1002/PROS.22456
Mei Mei, Yu Ren, Xuan Zhou, Xu-bo Yuan, Lei Han, Guang-xiu Wang, Zhifan Jia, Pei-yu Pu, Chun-sheng Kang, Zhi Yao, Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells Technology in Cancer Research & Treatment. ,vol. 9, pp. 77- 86 ,(2010) , 10.1177/153303461000900109
Miao Zhong, Xin Ma, Caijun Sun, Ling Chen, MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer Chemico-Biological Interactions. ,vol. 184, pp. 431- 438 ,(2010) , 10.1016/J.CBI.2010.01.025
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857